⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 27, 2024Diabetes Obesity and MetabolismOpen Access

Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes

Anukriti Sharma Arshiya Mariam Emily Zacherle Alex Milinovich Janine Bauman David Sugano Josh Noone Jigar Rajpura Robert S. Zimmerman Bartolomé Burguera Michael W. Kattan Anita D. Misra‐Hebert Kevin M. Pantalone Daniel M. Rotroff

View Full Paper

Ask AI

Bookmark

Share

Abstract

To investigate the independent contributions of glycated haemoglobin (HbA1c) reduction and weight loss to clinical outcomes in patients with type 2 diabetes (T2D) treated with antidiabetic drugs, including glucagon-like peptide-1 receptor agonists (GLP-1RAs).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sharma et al. (2024) studied this question.

synapsesocial.com/papers/68e5ab93b6db6435875455c1 https://doi.org/10.1111/dom.15896

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilitiesClinical Trial · 2019 · 222 citations
2Predictive factors of body weight loss in patients with type 2 diabetes treated with GLP-1 receptor agonists: a 52-week prospective real-life study2025 · 12 citations
3Early weight loss, diabetes remission and long-term trajectory after diagnosis of type 2 diabetes: a retrospective studycohort · 2025 · 15 citations
4Glucagon-like peptide-1 agonists’ effects on glycemic control, weight loss, and beta cells function in type 1 diabetesMeta-Analysis · 2026 · 2 citations
5Combination of GLP‐1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort studyCohort Study · 2019 · 18 citations

6680 GLP-1 Agonists in Type 1 Diabetes - Indications and Use2024
Adiponectin may play a crucial role in the metabolic effects of GLP-1RAs treatment in patients with Type 2 Diabetes Mellitus: a preliminary longitudinal study2024
Baseline phenotypes with preserved β-cell function and high insulin concentrations have the best improvements in glucose tolerance after weight loss: results from the prospective DEXLIFE and EGIR-RISC studies2024
Assessment of Non‐Invasive Tests for MASLD , MASH and At‐Risk MASH in a Multicentre Prospective Real‐World StudyDiabetes Obesity and Metabolism · 2026
Interpreting Diabetic Retinal Outcomes After GLP ‐1 Receptor Agonist and Tirzepatide Initiation: Clinical Evidence and Its LimitsDiabetes Obesity and Metabolism · 2026

More from Diabetes Obesity and Metabolism

More from Cleveland Clinic

More from Cleveland Clinic Lerner College of Medicine

More from Novo Nordisk (United States)